in the following description , various aspects of the invention will be described . for the purposes of explanation , specific details are set forth in order to provide a thorough understanding of the invention . it will be apparent to one skilled in the art that there are other embodiments of the invention that differ in details without affecting the essential nature thereof . therefore the invention is not limited by that which is described in the specification , but only as indicated in the accompanying claims , with the proper scope determined only by the broadest interpretation of said claims . the invention comprises a solution of glycerol in water . in preferred embodiments of the invention , 2 . 5 g of glycerol are present in each 100 ml of the prepared solution . in some embodiments of the invention , in the solution the salt concentration is less than 2 mm . in preferred embodiments of the invention , the glycerol solution is isotonic . in preferred embodiments of the invention , the viscosity of the solution is controlled by addition of a quantity of high molecular weight polymer ( mw & gt ; 10 4 dalton ) such as hyaluronate or carbomer sufficient to bring the solution to the desired viscosity . all ingredients are of purity sufficient for use in eye drops . the solutions are then transferred to a container appropriate for dispensing it as eye drops . in other embodiments of the invention , the solution additionally comprises a pharmaceutically effective concentration at least one pharmacologically active agent . if necessary , any stabilizer , preservative , antioxidant , buffer or combination thereof appropriate for use with the pharmacologically active agent may be added to the solution in any concentration suitable for use in eye drops . a typical protocol for use of the resulting eye drops to treat or to alleviate the symptoms of conjunctivochalasis is to place drops in the affected eye 3 times daily until the severity of the symptoms is reduced to an acceptable level . in particularly severe cases , more frequent applications may be necessary , and in less severe cases , a single daily dose may be sufficient . a solution , containing less than 2 mm salt , was prepared as described in example 2 above . the solution was then administered on average 3 times daily to a group of patients . the severity of the conjunctivochalasis was measured according to the lipcof ( lid parallel conjunctival folds ) scale , in which 0 represents the least severe level and 3 is very severe . determinations of the severity of the conjunctivochalasis were made prior to treatment , one month after the start of treatment , and 6 months after the start of treatment . the results are summarized in table 1 . the changes from the first lipcof determination to the second , and from the first to the third , are statistically significant at the p & lt ; 0 . 01 level . twenty patients suffering from conjunctivochalasis who had been using as a palliative measure commercially available artificial tear solutions known in the art were treated with the eye drops of the present invention . prior to treatment with the eye drops of the present invention , the patients had been using commercially available artificial tear solutions for periods of time ranging from two weeks to three years . nonetheless , the patients &# 39 ; average lipcof score was 2 . 8 , demonstrating that the artificial tear solutions known in the art are ineffective against conjunctivochalasis . the patients were then treated with the eye drops of the present invention , on average 4 times daily . the results of the study are given in table 2 , where the letters a - j represent the different commercially available artificial tear compositions that were used prior to the beginning of treatment with the eye drops of the present invention . after one month of treatment with the eye drops of the present invention , a statistically significant reduction ( p ≦ 0 . 001 ) in the average lipcof score was obtained , demonstrating the effectiveness of the present invention as a non - surgical treatment for conjunctivochalasis over artificial tear solutions known in the prior art .
an ophthalmic preparation and method , usable to treat conjunctivochalasis . the ophthalmic preparation comprises an aqueous solution of glycerol . the preparation may also include additional components including high molecular weight polymers for viscosity control and pharmacologically active substances . the method includes administering an ophthalmic preparation including an aqueous solution of glycerol to a patient .